

**SUPPLEMENTAL TABLE 1:** Additional baseline patient characteristics for each study included in the meta-analysis.

Study		1	2	3	4	5	6	7	8	9	10	11	12
Study Year		2008	2011	2011	2007	2010	2008	2008	2010	2012	2011	2008	2013
Number of Procedures with Response Assessment		168	40	10	33	51	9	16	48	23	10	8	19
Mean Age (Years)		58*	62	53*	61	61	59*	61	60	58	49	56*	62.5*
Female Patients		51%	29%	54%	35%	33%	78%	50%	40%	N/A	50%	37%	39%
Male Patients		49%	71%	46%	65%	67%	22%	50%	60%	N/A	50%	63%	61%
Mean Lab Values Prior to Treatment	Albumin (g/L)	N/A	72* <sup>†</sup> (7.2) <sup>‡</sup>	N/A	N/A	N/A	N/A	39 (3.9)	38 (3.8)	N/A	N/A	37 (3.7)	N/A
	AP (μkat/L)	N/A	2.5* (152)	N/A	N/A	N/A	N/A	3.3 (197)	2.2 (131)	N/A	N/A	4.1 (248)	N/A
	AST(μkat/L)	N/A	0.57* (34)	1.5 (91)	N/A	N/A	N/A	0.65 (39)	0.63 (38)	N/A	N/A	0.91 (54.5)	N/A
	ALT(μkat/L)	N/A	0.55* (33)	0.68 (41)	N/A	N/A	N/A	0.75 (45)	0.82 (49)	N/A	N/A	(0.62) 37	N/A
	TB (μmol/L)	N/A	10.3* (0.6)	8.6 (0.5)	N/A	N/A	N/A	12 (0.7)	18.8 (1.1)	N/A	N/A	6.8 (0.4)	N/A
	GGT (μkat/L)	N/A	2.6* (158)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Mean Time Elapsed from NET Diagnosis to Y90 Treatment (Months)		N/A	27.4*	N/A	55.9	34.9	59 <sup>§</sup>	N/A	N/A	N/A	30%	N/A	N/A
ECOG Score	0	Median ECOG: 0	74%	N/A	N/A	68%	N/A	N/A	50%	79%	N/A	N/A	N/A
	1		17%	N/A	N/A	24%	N/A	N/A	25%		N/A	N/A	N/A
	2		9%	N/A	N/A	6%	N/A	N/A	4%	21%	N/A	N/A	N/A
	3		0%	N/A	N/A	2%	N/A		0%	0%	N/A	N/A	N/A

\*These studies reported the value as a median.

<sup>†</sup>This study reported the albumin level as whole protein.

<sup>‡</sup>The units in parentheses are in grams/deciliter for albumin, units/liter for AP, AST, ALT, and GGT and milligrams/deciliter for TB.

<sup>§</sup>Unclear if time elapsed since primary neuroendocrine tumor or neuroendocrine liver metastases diagnosis.

ECOG unknown in 21% of patients.

1: Kennedy; 2: Paprottka; 3: Lacin; 4 :King; 5: Cao; 6: Kalinowski; 7: Rhee; 8: Saxena; 9: Ezzidin; 10: Arslan; 11: Murthy; 12: Ozao-Choy; N/A: Not available; g/L: grams/liter; AP: Alkaline phosphatase; μkat/L: microkatal/liter; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; TB: Total bilirubin; μmol/L: micromole/liter; GGT: Gamma glutamyl transferase; NET: Neuroendocrine tumor; Y90: Yttrium-90; ECOG: Eastern Cooperative Oncology Group

**SUPPLEMENTAL TABLE 2:** Overview of the current literature.

Author (year)	Study design	Treatment	N	L	RA Criteria	CR	PR	MS
Rinke (2009)(1)	RCT	Octreotide	42	83%	WHO	0%	2.4%	N/R
		Placebo	43	88%		0%	2.3%	73.7 <sup>*</sup>
Arnold (2005)(2)	RCT	Octreotide	51	N/A	>50%	0%	1%	35
		Octreotide + Interferon	54			0%	1.9%	51
Ramanathan (2001)(3)	Prospective	Dacarbazin	52 (50) <sup>‡</sup>	N/A	>50%	8%	26%	19.3
Iwasa (2010)(4)	Retrospective	Cisplatin + Etoposide (PDNET)	21	81%	RECIST	0%	14.3%	5.8
Mitry (1999)(5)	Retrospective	Cisplatin + Etoposide (WDNET)	12	N/A	WHO	0%	9%	17.6
		Cisplatin + Etoposide (PDNET)	41			9.8%	31.7%	15
Turner (2010)(6)	Prospective	5-FU + Cisplatin + Streptozocin	82	76%	RECIST	0%	32.9%	31.5
Olsen (2012)(7)	Prospective	Temozolomide (PDNET)	28	86%	RECIST	0%	0%	3.5
Fine (2013)(8)	Retrospective	CAPTEM (WDNET)	18	100%	RECIST	5.6%	55.6%	83 <sup>*</sup>
Strosberg (2011)(9)	Retrospective	CAPTEM (WDNET)	30	NA	RECIST	0%	70%	N/R
Pavel (2011)(10)	RCT	Placebo + Octreotide	213	92%	RECIST	0%	1.9%	N/A
		Everolimus + Octreotide	216	92%		0%	2.3%	
Yao (2010)(11)	Prospective	Everolimus	115	95%	RECIST	0%	9.6%	24.9
		Everolimus + Octreotide	45	93%	RECIST	0%	4.4%	N/R
Raymond (2011)(12)	RCT	Placebo	85	94%	RECIST	0%	0%	N/R
		Sunitinib	86	95%		2.3%	7%	N/R
Imhof (2011)(13)	Prospective	<sup>90</sup> Y-DOTA-TOC	1109	N/A	N/A	0.6% <sup>‡</sup>	N/A	94.6 <sup>*</sup>
Villard (2012)(14)	Prospective	<sup>90</sup> Y-DOTA-TOC	237	88%	RECIST	3.4%	16%	47.5
		<sup>90</sup> Y-DOTA-TOC + <sup>177</sup> Lu-DOTA-TOC	249	76%		2.2%	20.9%	66.1
Kwekkeboom (2008)(15)	Retrospective	<sup>177</sup> Lu-DOTA-TATE	310	89%	SWOG	1.6%	27.7%	46
Claringbold (2012)(16)	Prospective	<sup>177</sup> Lu-DOTA-TATE + CAPTEM	34	94%	RECIST	14.7%	38.2%	N/R
Berber (2002)(17)	Prospective	RFA	34	100%	N/A	N/A	N/A	19.2 <sup>§</sup>
Gillams (2005)(18)	Prospective	Laser thermal ablation or RFA	25	100%	N/A	N/A	N/A	29
Strosberg (2005)(19)	Retrospective	TAE	84 (23) <sup>‡</sup>	100%	RECIST	0%	47.8%	36
Ruutiainen (2007)(20)	Retrospective	TAE	23	100%	RECIST	0%	50%	39
		TACE	44			0%	66%	44
Dong (2011)(21)	Retrospective	TACE	123	100%	RECIST	0%	61.8%	65.6 <sup>§</sup>
Strosberg (2012)(22)	Prospective	TAE directly followed by Sunitinib	39	100%	RECIST	0%	72%	N/R
Kratochwil (2011)(23)	Prospective	Transarterial <sup>90</sup> Y- or <sup>177</sup> Lu-DOTA-TOC	15	100%	RECIST	6.7%	53.3%	N/A
Limouris (2008)(24)	Prospective	Transarterial <sup>111</sup> In-pentetreotide	17	100%	RECIST	5.9%	47.1%	32

\*Months since diagnosis.

‡Number of patients available for response assessment.

‡Own definition of response: CR: Disappearance of all lesions; (PR not well defined)

§Mean survival

N: Number of patients; L: Liver involvement; RA: Response assessment; CR: Complete response; PR: Partial response; MS: Median survival (months); N/R: Not reached in study; N/A: Not available; >50%: More than 50% decrease in tumor size; PDNET: poorly differentiated neuroendocrine tumor; WDNET: well differentiated neuroendocrine tumor; CAPTEM: capecitabine and temozolomide

## SUPPLEMENTAL REFERENCES

1. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. *J Clin Oncol.* 2009;27:4656-4663.
2. Arnold R, Rinke A, Klose KJ, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. *Clin Gastroenterol Hepatol.* 2005;3:761-771.
3. Ramanathan RK, Cnaan A, Hahn RG, et al. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. *Ann Oncol.* 2001;12:1139-1143.
4. Iwasa S, Morizane C, Okusaka T, et al. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. *Jpn J Clin Oncol.* 2010;40:313-318.
5. Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. *Br J Cancer.* 1999;81:1351-1355.
6. Turner NC, Strauss SJ, Sarker D, et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. *Br J Cancer.* 2010;102:1106-1112.
7. Olsen IH, Sorensen JB, Federspiel B, et al. Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas. *Scientific World Journal.* 2012;170496:4 pages.
8. Fine RL, Gulati AP, Krantz BA, et al. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: the pancreas center at Columbia university experience. *Cancer Chemother Pharmacol.* 2013;71:663-670.

9. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. *Cancer*. 2011;117:268-275.
10. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. *Lancet*. 2011;378:2005-2012.
11. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. *J Clin Oncol*. 2010;28:69-76.
12. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. *N Engl J Med*. 2011;364:501-513.
13. Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. *J Clin Oncol*. 2011;29:2416-2423.
14. Villard L, Romer A, Marincek N, et al. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. *J Clin Oncol*. 2012;30:1100-1106.
15. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. *J Clin Oncol*. 2008;26:2124-2130.
16. Claringbold PG, Price RA, Turner JH. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade

neuroendocrine tumors. *Cancer Biother Radiopharm.* 2012;27:561-569.

17. Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. *World J Surg.* 2002;26:985-990.
18. Gillams A, Cassoni A, Conway G, et al. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. *Abdom Imaging.* 2005;30:435-441.
19. Strosberg JR, Choi J, Cantor AB, et al. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. *Cancer Control.* 2006;13:72-78.
20. Ruutiainen AT, Soulen MC, Tuite CM, et al. Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. *J Vasc Interv Radiol.* 2007;18:847-855.
21. Dong XD, Carr BI. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. *Med Oncol.* 2011;28:S286-290.
22. Strosberg JR, Weber JM, Choi J, et al. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. *Ann Oncol.* 2012;23:2335-2341.
23. Kratochwil C, Lopez-Benitez R, Mier W, et al. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. *Endocr Relat Cancer.* 2011;18:595-602.
24. Limouris GS, Chatziioannou A, Kontogeorgakos D, et al. Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases. *Eur J Nucl Med Mol Imaging.* 2008;35:1827-1837.